Roble Belko & Company’s Rhythm Pharmaceuticals RYTM Stock Holding History

Roble Belko & Company’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-15	Closed	–	–	349
2019 Q2	$0	Buy	+15	New	+$379	﹤0.01%	357

Other funds holding RYTM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Roble Belko & Company's RYTM Position: Q3 2019 in Review

Roble Belko & Company sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2019, closing a stake of 15 shares.

Roble Belko & Company first reported a position in RYTM in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 84 funds tracked by Wall St. Rank hold RYTM as of Q3 2019.

Roble Belko & Company reported no remaining Rhythm Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Roble Belko & Company sold 15 Rhythm Pharmaceuticals shares in Q3 2019.
Roble Belko & Company first reported a position in Rhythm Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Roble Belko & Company's Rhythm Pharmaceuticals position peaked at $0 in Q2 2019.
84 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2019.

Based on Roble Belko & Company's 13F filing for Q3 2019, filed 13 Nov 2019.